^
    3d
    The safety and efficacy of Osimertinib plus Capivasertib in EGFRm advanced non-small cell lung cancer (NSCLC) participants with PIK3CA/AKT1/PTEN alterations who had progressed on first-line Osimertinib monotherapy or plus chemotherapy: a first-in-human, phase Ib/Ⅱa study (PRECISION) (ChiCTR2600116135)
    P1/2, N=47, Not yet recruiting, Cancer Hospital of Shanxi Province; Cancer Hospital of Shanxi Province
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • PTEN mutation • AKT1 mutation
    |
    Tagrisso (osimertinib) • Truqap (capivasertib) • simmitinib (SYHA1817)
    5d
    A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants (clinicaltrials.gov)
    P1, N=18, Recruiting, AstraZeneca | Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Truqap (capivasertib)
    6d
    SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov)
    P1, N=396, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Jun 2027
    Trial completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • anastrozole • camizestrant (AZD9833)
    12d
    Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1. (PubMed, ESMO Open)
    In these pretreated participants, camizestrant 75 mg in combination with capivasertib 400 mg was well tolerated, with a side effect profile consistent with each drug as monotherapy, and showed encouraging evidence of clinical efficacy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    ER positive • HER-2 negative • EGFR positive • HER-2 negative + ER positive
    |
    fulvestrant • Truqap (capivasertib) • camizestrant (AZD9833)
    12d
    A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment (clinicaltrials.gov)
    P1, N=20, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Truqap (capivasertib)
    17d
    A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy (PubMed, Gan To Kagaku Ryoho)
    In the CAPItello-291 trial, capivasertib and fulvestrant demonstrated efficacy in patients with up to two prior lines endocrine therapy, but its use in late-line settings has not yet been reported. In this article, we report a case of a woman with metastatic recurrent breast cancer who was treated with capivasertib and fulvestrant was used as the late-line treatment, resulting in a progression-free survival of 8 months.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation • HR positive + HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    19d
    A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    Truqap (capivasertib)
    21d
    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24
    Enrollment closed • Enrollment change • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • everolimus • tamoxifen • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • Truqap (capivasertib) • letrozole • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)
    21d
    CAPItrue: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (clinicaltrials.gov)
    P3, N=300, Recruiting, AstraZeneca | N=560 --> 300
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • Truqap (capivasertib)
    21d
    CAPItana: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (clinicaltrials.gov)
    P3, N=101, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    22d
    A071401: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas (clinicaltrials.gov)
    P2, N=124, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • PTCH1 (Patched 1) • CDK4 (Cyclin-dependent kinase 4) • NF2 (Neurofibromin 2) • SMO (Smoothened Frizzled Class Receptor) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3)
    |
    PIK3CA mutation • PTEN mutation • AKT1 mutation
    |
    Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098
    22d
    AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era. (PubMed, J Comput Aided Mol Des)
    Top-ranked peptides, such as Gitoxoside (- 11.53 kcal/mol) and 9-Fluoro-11 (- 11.38 kcal/mol), demonstrated stronger binding to AKT1 than the reference inhibitor Capivasertib (- 8.50 kcal/mol)...Collectively, this integrative AI framework efficiently explores peptide chemical space, enabling the rapid identification of peptide-based and peptidomimetic inhibitors with strong binding affinity and stability. The findings highlight the potential of AI-assisted peptide design as a scalable and cost-effective strategy for developing next-generation therapeutics against endometrial cancer.
    Journal
    |
    ER (Estrogen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Truqap (capivasertib)